Insider Selling: Neurocrine Biosciences (NASDAQ:NBIX) Director Sells $1,093,425.00 in Stock

Key Points

• Director George Morrow sold 7,500 shares for $1.09 million under a pre-arranged Rule 10b5-1 plan, reducing his stake by 41.93%; he retained 10,386 shares.
• Neurocrine reported quarterly EPS of $3.29, beating the $1.91 consensus, while revenue rose 41.3% year over year to $1.12 billion.
• The stock climbed 13.4% to $164.85. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $201.55.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director George Morrow sold 7,500 shares of the company's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $145.79, for a total value of $1,093,425.00. Following the sale, the director owned 10,386 shares in the company, valued at $1,514,174.94. The trade was a 41.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Up 13.4%

NASDAQ:NBIX traded up $19.50 during trading hours on Tuesday, reaching $164.85. 4,056,875 shares of the stock were exchanged, compared to its average volume of 1,234,742. The stock has a market capitalization of $16.76 billion, a P/E ratio of 24.17, a P/E/G ratio of 0.64 and a beta of 0.36. The firm has a 50 day simple moving average of $146.49 and a 200-day simple moving average of $147.45. Neurocrine Biosciences, Inc. has a 52 week low of $122.14 and a 52 week high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported $3.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.91 by $1.38. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.04 billion. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The business's quarterly revenue was up 41.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.04 EPS. As a group, analysts expect that Neurocrine Biosciences, Inc. will post 7.72 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on NBIX. Truist Financial increased their target price on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. BMO Capital Markets decreased their price target on shares of Neurocrine Biosciences from $164.00 to $150.00 and set a "market perform" rating for the company in a report on Monday, October 12th. Morgan Stanley boosted their price objective on shares of Neurocrine Biosciences from $183.00 to $185.00 and gave the company an "equal weight" rating in a research report on Tuesday. Guggenheim initiated coverage on shares of Neurocrine Biosciences in a research report on Tuesday, October 6th. They set a "buy" rating and a $207.00 price objective for the company. Finally, Citigroup increased their price objective on shares of Neurocrine Biosciences from $249.00 to $253.00 and gave the stock a "buy" rating in a research note on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of "Moderate Buy" and an average price target of $201.55.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NBIX. BlackRock Inc. acquired a new position in shares of Neurocrine Biosciences during the second quarter valued at $2,310,886,000. Renaissance Technologies LLC grew its position in shares of Neurocrine Biosciences by 8.0% during the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company's stock worth $318,665,000 after acquiring an additional 180,100 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Neurocrine Biosciences by 97.0% in the 1st quarter. First Trust Advisors LP now owns 959,217 shares of the company's stock worth $126,367,000 after acquiring an additional 472,408 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter worth about $117,827,000. Finally, Ieq Capital LLC acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter worth about $107,914,000. 92.59% of the stock is currently owned by institutional investors.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Quarterly results topped expectations. Revenue increased 41% year over year to $1.12 billion, and earnings were $3.29 per share. Product sales exceeded $1 billion for the first time, with strong demand across the portfolio. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA guidance was raised. Neurocrine now expects 2026 net sales of $2.9 billion to $2.925 billion, reflecting continued demand for its leading product. The company also cited growth from Crenessity. NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
• Positive Sentiment: Several analysts lifted price targets. Canaccord raised its target to $220 and kept a Buy rating; Piper Sandler raised its target to $215 with an Overweight rating, and RBC raised its target to $190 with an Outperform rating. Canaccord Genuity Group recommendations
• Neutral Sentiment: Neurocrine announced a Phase 2 Alzheimer’s study and plans to present its scientific and neuropsychiatry pipeline at the NEI Fall Congress. These developments may support longer-term pipeline visibility, but no study results were reported. Neurocrine Starts Phase 2 Alzheimer’s Study
• Neutral Sentiment: Morgan Stanley raised its price target to $185 but maintained an Equal Weight rating, signaling a more cautious view than the other target increases. Morgan Stanley recommendations

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company's research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine's leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.